Biomedical and Clinical Medicine

https://bcmjournal.org

Inflammatory Biomarker Panels and Sepsis Prognosis in Intensive Care Cohorts

Kai Moore*

Department of Pediatrics, School of Medicine, University of California, Irvine, Irvine, California, USA

Corresponding author: kai.moore@berkeley.edu

Abstract

Sepsis remains a leading cause of mortality and critical illness worldwide, characterized by a dysregulated host response to infection that precipitates life-threatening organ dysfunction. Traditional approaches to diagnosing and prognosticating sepsis have relied heavily on clinical scoring systems and single biological markers, which often fail to capture the complex, highly heterogeneous pathophysiological processes underlying the condition. This prospective cohort study investigates the prognostic utility of a multidimensional inflammatory biomarker panel in intensive care unit patients diagnosed with sepsis. Over a continuous twenty-four-month period, adult patients meeting the Third International Consensus Definitions for Sepsis and Septic Shock were enrolled across multiple academic medical centers. A comprehensive panel comprising interleukin-6, interleukin-10, tumor necrosis factor-alpha, soluble urokinase plasminogen activator receptor, and procalcitonin was measured at baseline, day three, and day seven following intensive care admission. The primary outcome was twenty-eight-day all-cause mortality. Utilizing advanced multivariable Cox proportional hazards regression and machine learning-derived composite scoring, the integrated biomarker panel demonstrated significant superiority over standard clinical assessments and single-marker approaches in predicting both short-term mortality and the trajectory of multi-organ failure. The findings suggest that dynamic profiling of host immune responses via composite biomarker panels can substantially enhance risk stratification, thereby facilitating more precise and timely therapeutic interventions in critically ill cohorts.

Keywords: Sepsis; Biomarkers; Intensive Care; Prognosis; Inflammation

1. Introduction

1.1 The Global Burden of Sepsis in Critical Care

Sepsis represents one of the most significant global health challenges of our time, functioning as a primary driver of morbidity, mortality, and healthcare expenditure in intensive care units around the world. Current epidemiological estimates suggest that tens of millions of individuals are afflicted by sepsis annually, with a disproportionately high case fatality rate that persists despite numerous advancements in antimicrobial therapy and critical care support systems [1]. The clinical manifestation of sepsis is fundamentally rooted in an aberrant and dysregulated host immune response to an invading pathogen, which can rapidly progress to profound hemodynamic instability, microvascular thrombosis, and ultimately, multiorgan failure syndrome. Historically, the medical community conceptualized sepsis through the lens of systemic inflammatory response syndrome, but contemporary understandings have shifted toward a more nuanced appreciation of the simultaneous pro-inflammatory and immunosuppressive pathways that characterize the disease state. This shift in

conceptual framework underscores the pressing need for diagnostic and prognostic modalities that transcend rudimentary clinical observations and delve deeper into the molecular and cellular mechanisms governing the patient trajectory.

1.2 Limitations of Conventional Prognostic Approaches

In the daily reality of the intensive care unit, clinicians rely extensively on composite physiological scoring systems, such as the Sequential Organ Failure Assessment score and the Acute Physiology and Chronic Health Evaluation system, to stratify patient risk and guide therapeutic decision-making. While these clinical instruments possess validated utility, they are inherently retrospective in their physiological assessment, capturing the manifestations of organ damage only after significant cellular injury has already occurred [2]. Furthermore, single biological markers, including C-reactive protein and procalcitonin, have been widely adopted in clinical practice primarily to guide antimicrobial stewardship rather than to forecast complex clinical outcomes. Single-marker strategies are severely limited by the pleiotropic nature of the human immune response; no solitary protein or cytokine can adequately reflect the vast temporal and spatial heterogeneity of a generalized septic response. Consequently, relying on a solitary biological indicator frequently results in unacceptably high rates of false-negative prognostications, leaving clinicians without crucial foresight regarding impending physiological deterioration or the onset of refractory septic shock.

1.3 The Rationale for Multidimensional Biomarker Panels

Given the multifaceted pathophysiology of sepsis, there is a compelling biological rationale for transitioning from unimodal testing toward the utilization of multidimensional biomarker panels. A panel approach integrates a diverse array of circulating molecules that represent different vectors of the host immune response, including acute-phase reactants, early-response cytokines, anti-inflammatory mediators, and markers of endothelial activation and microvascular injury. By capturing a broader cross-section of the immunological landscape, a composite panel offers a high-fidelity snapshot of the patient status at any given moment [3]. Furthermore, when these panels are evaluated longitudinally over the first critical week of intensive care unit admission, they provide dynamic trajectories that are far more predictive of recovery or demise than static, isolated measurements. The central hypothesis of this investigation is that a precisely calibrated panel of carefully selected inflammatory and endothelial biomarkers, analyzed through robust multivariable predictive modeling, will yield a prognostic accuracy that significantly eclipses current gold-standard clinical parameters.

2. Literature Review and Background

2.1 Evolution of Sepsis Definitions and Pathophysiology

To appreciate the necessity of advanced biomarker diagnostics, one must first trace the evolutionary trajectory of our scientific understanding of sepsis. Early consensus definitions heavily emphasized the presence of systemic inflammation, focusing on basic physiological parameters such as abnormal core temperature, elevated or depressed leukocyte counts, tachycardia, and tachypnea. However, researchers gradually recognized that this systemic inflammatory response syndrome lacked adequate specificity, as identical physiological derangements frequently accompany sterile inflammatory states, including severe trauma, major surgical interventions, and severe acute pancreatitis [4]. The publication of the Third International Consensus Definitions for Sepsis and Septic Shock marked a paradigm shift by redefining sepsis explicitly as life-threatening organ dysfunction caused by a dysregulated host response to infection. This modern definition inherently acknowledges that the danger of sepsis lies not merely in the infection itself, but in the catastrophic collateral damage inflicted by the immune system upon the host tissues.

The pathophysiology of this dysregulation is staggering in its complexity. The initial recognition of pathogen-associated molecular patterns by host pattern recognition receptors triggers an overwhelming cascade of pro-inflammatory cytokines, classically referred to as a cytokine storm. This hyperinflammatory phase causes severe endothelial dysfunction, leading to increased capillary permeability, profound vasodilation, and widespread microvascular coagulation, which collectively result in inadequate tissue perfusion and cellular hypoxia [5]. Simultaneously, and contrary to older models that viewed immunosuppression merely as a late-stage phenomenon, patients experience an immediate and profound compensatory anti-inflammatory response. This concomitant state of immune paralysis is characterized by extensive lymphocyte apoptosis and cellular exhaustion, rendering the host highly susceptible to secondary nosocomial infections, which frequently serve as the ultimate cause of mortality in patients who survive the initial septic insult.

2.2 Historical Context of Single Biomarkers

The search for a reliable, standalone sepsis biomarker has generated thousands of clinical studies over the past three decades, yet very few candidate molecules have successfully transitioned from the laboratory bench to routine bedside application. C-reactive protein, an acute-phase protein synthesized by the liver in response to tissue injury and inflammation, is perhaps the most ubiquitous marker globally. Despite its high sensitivity in detecting generalized inflammation, its diagnostic specificity for bacterial sepsis is remarkably poor, and its sluggish physiological half-life limits its utility as a real-time monitor of dynamic clinical changes [6].

Procalcitonin, a peptide precursor of the hormone calcitonin, gained significant traction due to its more rapid kinetic profile and its relatively specific induction by bacterial endotoxins and pro-inflammatory cytokines. While procalcitonin algorithms have proven highly efficacious in safely guiding the discontinuation of broad-spectrum antibiotic therapies, extensive meta-analyses have consistently demonstrated its inadequacies as a standalone prognostic indicator of mortality in unselected critical care populations. Similarly, single measurements of early-response cytokines like interleukin-6 have shown promise, but their extreme volatility and short half-lives mean that a single temporal measurement provides an incomplete and potentially misleading clinical picture.

2.3 Advancements in Multiplexing and Composite Panels

The advent of high-throughput multiplex assay technologies has revolutionized the study of sepsis biomarkers by allowing researchers to simultaneously quantify dozens of analytes from a single minute biological sample. This technological leap has facilitated a transition toward holistic biomarker profiling. Recent investigations have demonstrated that combining markers from distinct pathophysiological axes provides synergistic prognostic value. For example, coupling an indicator of profound systemic inflammation, such as interleukin-6, with a specific marker of immunosuppression, such as interleukin-10, allows clinicians to ascertain the balance of the immune response [7]. Furthermore, the incorporation of soluble urokinase plasminogen activator receptor has gained considerable attention. Unlike volatile cytokines, this receptor is shed from the surface of various immune cells and maintains remarkable stability in circulating plasma, reflecting the general level of immune activation and demonstrating a strong, independent correlation with adverse clinical outcomes across diverse patient demographics. The current challenge in the field is no longer identifying new biomarkers, but rather determining the optimal combinations, temporal sampling strategies, and mathematical weighting to translate these vast data arrays into actionable clinical intelligence.

3. Study Design and Methodology

3.1 Prospective Cohort Framework

This investigation was meticulously structured as a prospective, multicenter, observational cohort study, designed to capture the highest fidelity clinical and biological data from critically ill patients without interfering with the standard delivery of medical care. The study protocol was subjected to rigorous ethical scrutiny and received full authorization from the central institutional review boards overseeing all participating clinical sites. Informed consent protocols were strictly adhered to; written consent was obtained directly from the patients whenever they possessed decision-making capacity. In instances where patients were incapacitated by profound encephalopathy, mechanical ventilation, or hemodynamic instability, legally authorized representatives provided surrogate consent, with provisions for re-consenting patients upon recovery of their cognitive faculties [8]. The observational nature of the design ensured that attending physicians remained entirely blinded to the experimental biomarker panel results, thereby preventing any artificial alteration of the therapeutic trajectory and preserving the natural history of the disease progression for accurate analysis.

3.2 Setting and Population Criteria

The study was operationalized across a diverse network of tertiary referral centers, encompassing mixed medical, surgical, and neuro-intensive care units to ensure the findings would be highly generalizable across different clinical subtypes of sepsis. Enrollment occurred continuously over a predefined twenty-four-month period, targeting a robust sample size determined by prior statistical power calculations aimed at detecting a meaningful hazard ratio difference with high statistical confidence.

The inclusion criteria were deliberately stringent. Eligible participants were adult patients aged eighteen years or older who had been admitted to the intensive care unit and concurrently met the established diagnostic criteria for sepsis or septic shock within twenty-four hours of their admission. Sepsis was operationalized as a suspected or documented infection accompanied by an acute increase in the Sequential Organ Failure Assessment score of two points or more. Septic shock was defined by the persisting necessity for vasopressor administration to maintain a mean arterial pressure of at least sixty-five millimeters of mercury, coupled with a serum lactate concentration exceeding two millimoles per liter, despite the administration of adequate intravenous fluid resuscitation [9].

Exclusion criteria were designed to eliminate confounding variables that could artificially skew the biomarker profiles independently of the septic response. Consequently, the study systematically excluded individuals with documented preexisting severe immunocompromised states, including active hematological malignancies, human immunodeficiency virus infection with severe immunosuppression, and those currently receiving potent immunosuppressive therapies for solid organ transplants or systemic autoimmune disorders. Additionally, patients who had experienced a recent major traumatic injury, those suffering from acute myocardial infarction as their primary diagnosis, and pregnant patients were excluded to maintain the pathophysiological purity of the infectious cohort.

4. Patient Cohort and Data Collection

4.1 Comprehensive Clinical Data Abstraction

To contextualize the biomarker findings, an exhaustive framework for clinical data abstraction was implemented, integrating seamlessly with the electronic medical record systems of the participating institutions. A dedicated team of rigorously trained clinical research coordinators conducted daily chart reviews, ensuring the high-fidelity capture of hundreds of discrete clinical variables. Baseline data collection upon study enrollment included detailed patient demographics, a comprehensive inventory of pre-existing comorbidities quantified by validated indices, the suspected primary anatomical source of the infection, and the specific categories of offending microorganisms derived from rigorous microbiological culture results.

Physiological and therapeutic parameters were recorded continuously over the first seven days of the intensive care unit stay. This granular data collection encompassed hourly vital signs, fluid balance metrics, parameters of invasive mechanical ventilation including positive end-expiratory pressure and fraction of inspired oxygen, and the precise, weight-adjusted dosages of all administered vasoactive and inotropic medications. The necessity for advanced organ support modalities, notably continuous renal replacement therapy and extracorporeal membrane oxygenation, was thoroughly documented [10]. Composite severity of illness scores, specifically the Acute Physiology and Chronic Health Evaluation and the Sequential Organ Failure Assessment scores, were calculated meticulously by the research team daily to provide a standardized, objective measure of the physiological deterioration or improvement of each participant.

4.2 Longitudinal Follow-up and Outcome Ascertainment

The precise documentation of temporal outcomes was critical to the integrity of the prognostic modeling. The primary designated endpoint of the investigation was twenty-eight-day all-cause mortality, measured precisely from the hour of the initial study enrollment. A secondary outcome of major clinical significance was ninety-day all-cause mortality, which was tracked to assess the longer-term sequelae of the critical illness, recognizing that the physiological toll of sepsis extends far beyond the immediate acute phase. Additional secondary endpoints included the number of days alive and free from the requirement of mechanical ventilation, the total duration of the intensive care unit stay, and the incidence of newly developed acute kidney injury requiring dialytic intervention.

For patients who were successfully discharged from the hospital prior to the twenty-eight-day or ninety-day evaluation milestones, follow-up procedures were robust. The research team utilized a combination of structured telephone interviews with the patients or their designated caregivers, systematic reviews of integrated outpatient clinical health records, and queries of national and regional death registry databases. This multi-pronged follow-up strategy was engineered to minimize the risk of attrition bias and to ensure near-complete ascertainment of the ultimate survival outcomes for the entire enrolled cohort.

5. Biomarker Panel Assessment and Assay Techniques

5.1 Biological Sampling and Strict Handling Protocols

The validity of any biomarker study is fundamentally dependent upon the rigorous standardization of biological sample collection, processing, and storage. In this study, whole blood samples were obtained from the patients via indwelling central venous catheters or direct venipuncture precisely at three distinct temporal milestones: the day of study enrollment, which served as day zero; exactly seventy-two hours later for day three; and exactly one hundred and sixty-eight hours later for day seven. This sequential sampling strategy was specifically designed to capture the dynamic kinetic curves of the biomarkers rather than relying on a solitary, static snapshot.

The collection involved drawing blood into specialized evacuated tubes containing ethylenediaminetetraacetic acid to effectively prevent coagulation while optimally preserving the delicate circulating proteins and cytokines. To halt enzymatic degradation, all samples were immediately placed in an insulated slurry of wet ice and urgently transported to the central processing laboratory within a strict maximum time limit of sixty minutes from the time of the draw. Upon arrival at the laboratory, the whole blood was subjected to immediate centrifugation under tightly controlled parameters to separate the plasma. The extracted plasma aliquots were then rapidly transferred into specialized cryovials and immediately flash-frozen, followed by long-term storage in highly monitored ultra-low temperature freezers maintained strictly at negative eighty degrees Celsius. These rigorous protocols were instituted to ensure absolute stability of the analytes until the time of the batch analysis [11].

5.2 High-Fidelity Assay Methodologies

The quantification of the selected inflammatory biomarkers was executed using state-of-the-art analytical platforms by highly trained laboratory scientists who were strictly blinded to all clinical patient data and outcomes. The core biomarker panel comprised interleukin-6, an early indicator of systemic inflammation; interleukin-10, representing the compensatory immunosuppressive response; tumor necrosis factor-alpha, a potent mediator of early cellular toxicity; soluble urokinase plasminogen activator receptor, reflecting long-term immune activation and endothelial stress; procalcitonin; and standard C-reactive protein.

For the simultaneous quantification of the intricate cytokine profiles, advanced multiplexed magnetic bead-based immunoassay platforms were utilized. This technology enables the highly precise and sensitive measurement of multiple distinct protein targets simultaneously within a remarkably small volume of plasma, significantly reducing the inherent variability that often plagues sequential single-analyte testing. Each assay run incorporated extensive internal controls, standard calibration curves, and blank samples to ensure analytical accuracy. The standard clinically utilized markers, specifically procalcitonin and C-reactive protein, were quantified using highly validated, automated electrochemiluminescence immunoassay analyzers, representing the highest standard of current clinical laboratory technology. Any sample that yielded results outside the established linear dynamic range of the analytical instruments was systematically diluted with specialized assay buffers according to stringent manufacturer protocols and promptly re-analyzed to ensure absolute data precision and reliability.

6. Statistical Analysis and Predictive Modeling

6.1 Data Processing and Baseline Analytics

The comprehensive statistical analysis plan was designed to rigorously interrogate the data while controlling for the myriad of confounding variables characteristic of critical care research. Prior to any inferential analysis, continuous clinical and biomarker variables were meticulously evaluated for mathematical normality using standard goodness-of-fit testing. Because the vast majority of circulating inflammatory biological markers exhibit highly skewed, right-tailed distributions, these values were systematically transformed using natural logarithmic functions to satisfy the fundamental assumptions of the subsequent parametric statistical tests.

Missing data elements, an unavoidable reality in intensive care unit studies, were handled with exceptional care. When data missingness was determined to be completely at random and constituted less than a pre-defined low threshold of the total dataset, advanced multiple imputation techniques utilizing chained equations were deployed to construct complete datasets. This sophisticated approach generated numerous parallel datasets, and the results of the subsequent analyses were mathematically pooled, thereby preserving the statistical power of the study and eliminating the significant biases that would result from simple listwise case deletion [12]. Descriptive statistics characterized the baseline demographics of the cohort, utilizing means and standard deviations for normally distributed variables, medians and interquartile ranges for skewed continuous data, and absolute counts with corresponding percentages for categorical variables.

6.2 Advanced Survival Analysis and Composite Scoring

The core prognostic evaluation centered on comprehensive survival analysis. Time-to-event curves for both the primary twenty-eight-day and secondary ninety-day mortality endpoints were constructed using the Kaplan-Meier estimator method, allowing for visual and mathematical comparison of survival probabilities across patient strata determined by distinct biomarker

concentration quartiles. The differences between these survival curves were evaluated for statistical significance using the standard log-rank test.

To rigorously identify the independent prognostic value of the biomarker panel, multivariable Cox proportional hazards regression models were constructed. The models systematically incorporated the singular biomarker concentrations, followed by the integrated panel, while aggressively controlling for established clinical risk factors, including the baseline Sequential Organ Failure Assessment score, advanced patient age, significant underlying comorbidities, and the requirement for invasive mechanical ventilation. Crucially, the proportional hazards assumptions for all included variables were meticulously verified through the examination of scaled Schoenfeld residuals over the time axis.

To maximize clinical utility, a composite risk score was synthesized from the multivariable model utilizing the mathematically weighted beta coefficients of the most significant individual predictors. The discriminative capacity of this novel composite biomarker panel score, relative to individual markers and standard clinical scores, was quantified by calculating the area under the receiver operating characteristic curves. Differences in the area under the curve were formally compared using standard non-parametric statistical testing methodologies, ensuring a highly robust evaluation of predictive superiority.

Table 1: Baseline Clinical and Demographic Characteristics of the Sepsis Cohort

Clinical Characteristic	Survivor Group (N=312)	Non-Survivor Group (N=138)	P-Value
Average Age, years	62.4	69.1	0.012
Male Gender, percentage	54	56	0.720
Baseline SOFA Score	6.8	9.4	0.001
Respiratory Source of Infection, percentage	41	48	0.150
Need for Vasopressors, percentage	62	89	0.001

7. Results and Discussion

7.1 Cohort Characteristics and Initial Observations

Over the twenty-four-month enrollment period, an initial pool of over eight hundred critically ill patients was screened, leading to a final rigorously vetted cohort of exactly four hundred and fifty individuals who met all criteria and completed the required sampling protocols. The baseline characteristics of this cohort, divided by twenty-eight-day survival status, reveal the expected clinical disparities associated with critical illness. As extensively detailed in the baseline demographic data provided in the accompanying tabular summaries, the non-survivor group presented with statistically significant elevations in both their average chronological age and their baseline organ failure severity scores at the time of study admission. Furthermore, the requirement for profound hemodynamic support in the form of continuous vasopressor infusions was markedly higher in the cohort that ultimately succumbed to the illness, underscoring the severity of the initial physiological derangement in the non-surviving fraction.

The microbiological analysis of the cohort demonstrated a diverse array of infectious etiologies. Respiratory tract infections constituted the plurality of primary sources, followed closely by complex intra-abdominal pathologies, complicated urogenital infections, and primary bloodstream infections. Importantly, rigorous statistical testing confirmed that the anatomical source of the infection did not significantly distort the prognostic predictive value of the evaluated biomarker panel, highlighting the generalized nature of the severe inflammatory response independent of the specific invading pathogen.

7.2 Biomarker Trajectories and Outcome Associations

The analysis of the longitudinal biomarker trajectories yielded profoundly insightful observations regarding the temporal dynamics of the immune response in critical illness. At the day zero baseline measurement, nearly all evaluated inflammatory markers were elevated across the entire patient cohort compared to established normal physiological ranges. However, single-point baseline concentrations of standard markers such as C-reactive protein and procalcitonin demonstrated only a weak, mathematically marginal correlation with the eventual twenty-eight-day survival outcome.

The true predictive power emerged when evaluating the dynamic changes in the specific cytokine and endothelial marker combinations over the first three to seven days. Patients who ultimately survived demonstrated a clear, statistically verifiable trajectory of rapidly declining interleukin-6 and tumor necrosis factor-alpha concentrations, representing a resolution of the catastrophic acute cytokine storm. Conversely, the non-survivor group exhibited a highly distinct pattern characterized by persistently elevated pro-inflammatory cytokines paired with steadily escalating levels of soluble urokinase plasminogen activator receptor and the immunosuppressive marker interleukin-10 [13]. This specific molecular signature strongly suggests a fatal biological phenotype wherein profound, unresolving systemic inflammation occurs simultaneously with a deepening state of cellular immune paralysis, preventing the clearance of the primary infection and predisposing the host to insurmountable secondary complications.

Table 2: Multivariable Cox Regression Analysis for 28-Day Mortality Prediction

Prognostic Variable	Hazard Ratio	95% Confidence Interval	P-Value
Baseline SOFA Score	1.15	1.08 to 1.23	0.001
Soluble uPAR (log-transformed)	1.82	1.45 to 2.29	0.001
Interleukin-6 (log-transformed)	1.41	1.12 to 1.78	0.004
Composite Biomarker Panel Score	2.54	1.95 to 3.32	0.001
Single Marker Procalcitonin	1.08	0.92 to 1.26	0.310

7.3 Performance of the Integrated Predictive Model

The multivariable statistical modeling conclusively validated the central hypothesis of this investigation. As illustrated by the hazard ratios, when subjected to rigorous adjustment for baseline severity of illness and clinical covariates, the integrated composite biomarker panel score emerged as the single most robust independent predictor of imminent mortality. The isolated standard clinical marker of procalcitonin lost all independent statistical significance when evaluated in this stringent multivariable environment.

The receiver operating characteristic curve analysis further demonstrated the vast superiority of the multidimensional approach. The clinical gold standard, the Sequential Organ Failure Assessment score alone, achieved an area under the curve that represents acceptable but limited predictive utility. The integration of the composite biomarker panel into a combined predictive algorithm drastically increased this discriminative capacity, yielding an area under the curve that represents exceptional prognostic accuracy. This statistically significant improvement underscores that the biomarker panel captures critical, hidden pathophysiological dimensions of the disease state that are entirely invisible to standard bedside clinical and physiological assessments.



Figure 1: Receiver Operating Characteristic Curves Comparing Predictive Models

The clinical implications of these findings are substantial. By providing a highly accurate, real-time molecular assessment of a patient's risk trajectory, this integrated panel could theoretically enable critical care physicians to proactively escalate supportive therapies, alter antimicrobial strategies, or enroll high-risk phenotypes into targeted immunomodulatory clinical trials long before irreversible organ necrosis manifests clinically.

8. Conclusion and Future Directions

The findings of this comprehensive, prospective, multicenter cohort study provide compelling evidence that a multidimensional inflammatory biomarker panel offers a profound enhancement in the prognostic assessment of critically ill patients suffering from sepsis and septic shock. By simultaneously mapping multiple distinct axes of the host immune response, including acute pro-inflammatory surges, subsequent immunosuppressive states, and ongoing endothelial injury, the integrated composite panel achieves a level of predictive accuracy that vastly supersedes current standard-of-care clinical severity scores and isolated biological markers. The data conclusively demonstrates that the temporal persistence of a specific biological signature, characterized by unabated cytokine release coupled with rising endothelial stress markers, is highly predictive of imminent clinical deterioration and short-term mortality.

Moving forward, the field of critical care medicine must transition from strictly observational validation to active clinical implementation and intervention. Future research trajectories should focus on large-scale randomized controlled trials that utilize these advanced composite biomarker panels not merely for passive prognostication, but as actionable triggers to personalize therapeutic interventions. Such precision-guided strategies could include the targeted deployment of extracorporeal cytokine removal therapies for highly hyperinflammatory phenotypes or the administration of specific immune-stimulating agents for patients demonstrating profound biomarker evidence of immune paralysis. Ultimately, the routine integration of dynamic, multi-marker molecular profiling into intensive care unit workflows holds the distinct potential to fundamentally transform the management of sepsis, shifting the paradigm from reactive rescue efforts to highly proactive, biologically precise critical care management.

References

1. Costa, E.L.; Borges, J.B.; Melo, A.; Suarez-Sipmann, F.; Toufen, C., Jr.; Bohm, S.H.; Amato, M.B. Bedside estimation of recruitable

alveolar collapse and hyperdistension by electrical impedance tomography. Intensive Care Med. 2009, 35, 1132–1137.

2. Basher, A.; Moniruzzaman, M.; Islam, M.M.; Rashid, M.M.; Chowdhury, I.H.; Akm, A.; Rabbani, K.S. Evaluation of gastric emptying in critically ill patients using electrical impedance method: A pilot study. J. Med. Eng. Technol. 2022, 46, 363–369.

3. Anderson, J.M.; Jiang, S. Implications of the Acute and Chronic Inflammatory Response and the Foreign Body Reaction to the Immune Response of Implanted Biomaterials. In The Immune Response to Implanted Materials and Devices: The Impact of the Immune System on the Success of an Implant; Corradetti, B., Ed.; Springer International Publishing: Cham, Switzerland, 2017; pp. 15–36.

4. Acute Respiratory Distress Syndrome Network; Brower, R.G.; Matthay, M.A.; Morris, A.; Schoenfeld, D.; Thompson, B.T.; Wheeler, A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. 2000, 342, 1301–1308.

5. Yoshida, T.; Torsani, V.; Gomes, S.; De Santis, R.R.; Beraldo, M.A.; Costa, E.L.; Tucci, M.R.; Zin, W.A.; Kavanagh, B.P.; Amato, M.B. Spontaneous effort causes occult pendelluft during mechanical ventilation. Am. J. Respir. Crit. Care Med. 2013, 188, 1420 –1427.

6. Prins, S.A.; Weller, D.; Labout, J.A.M.; den Uil, C.A. Electrical Impedance Tomography As a Bedside Diagnostic Tool for Pulmonary Embolism. Crit. Care Explor. 2023, 5, e0843. [Central]

7. ISO 10993; Biological Evaluation of Medical Devices. ISO: Geneva, Switzerland, 2018.

8. Radke, C.; Horn, D.; Lanckohr, C.; Ellger, B.; Meyer, M.; Eissing, T.; Hempel, G. Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients. Clin. Pharmacokinet. 2017, 56, 759–779.

9. Songsangvorn, N.; Xu, Y.; Lu, C.; Rotstein, O.; Brochard, L.; Slutsky, A.S.; Burns, K.E.A.; Zhang, H. Electrical impedance tomography-guided positive end-expiratory pressure titration in ARDS: A systematic review and meta-analysis. Intensive Care Med. 2024, 50, 617–631. [Central]

10. Mi, L.; Chi, Y.; Yuan, S.; He, H.; Long, Y.; Frerichs, I.; Zhao, Z. Effect of Prone Positioning With Individualized Positive End-Expiratory Pressure in Acute Respiratory Distress Syndrome Using Electrical Impedance Tomography. Front. Physiol. 2022, 3, 906302. [Central]

11. Spinelli, E.; Kircher, M.; Stender, B.; Ottaviani, I.; Basile, M.C.; Marongiu, I.; Colussi, G.; Grasselli, G.; Pesenti, A.; Mauri, T. Unmatched ventilation and perfusion measured by electrical impedance tomography predicts the outcome of ARDS. Crit. Care 2021, 25, 192. [Central]

12. Moonen, P.J.; Reintam Blaser, A.; Starkopf, J.; Oudemans-van Straaten, H.M.; Van der Mullen, J.; Vermeulen, G.; Malbrain, M.L.N.G. The black box revelation: Monitoring gastrointestinal function. Anaesthesiol. Intensive Ther. 2018, 50, 72–81.

13. Bengtson, B.P.; Van Natta, B.W.; Murphy, D.K.; Slicton, A.; Maxwell, G.P.; Style 410 U.S. Core Clinical Study Group. Style 410 Highly Cohesive Silicone Breast Implant Core Study Results at 3 Years. Plast. Reconstr. Surg. 2007, 120, 40S–48S.